Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (3y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -2.19% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 64.73% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 30.89% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 60.12% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 29.56% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Nu-Med Plus | - | - | - | -31.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -31.93% |
| Sep 30, 2025 | 40.93% |
| Jun 30, 2025 | 41.43% |
| Mar 31, 2025 | 30.61% |
| Dec 31, 2024 | 54.54% |
| Sep 30, 2024 | 45.96% |
| Jun 30, 2024 | 58.54% |
| Mar 31, 2024 | 60.60% |
| Dec 31, 2023 | 51.87% |
| Sep 30, 2023 | 66.93% |
| Jun 30, 2023 | 70.09% |
| Mar 31, 2023 | 43.13% |
| Dec 31, 2022 | 30.12% |
| Sep 30, 2022 | 27.22% |
| Jun 30, 2022 | 38.38% |
| Mar 31, 2022 | 48.16% |
| Dec 31, 2021 | 31.56% |
| Sep 30, 2021 | 38.84% |
| Jun 30, 2021 | -13.97% |
| Mar 31, 2021 | -37.39% |
| Dec 31, 2020 | -28.67% |
| Sep 30, 2020 | -50.73% |
| Jun 30, 2020 | -104.29% |
| Mar 31, 2020 | -32.56% |
| Dec 31, 2019 | -30.52% |
| Sep 30, 2019 | 39.80% |
| Jun 30, 2019 | -12.90% |
| Mar 31, 2019 | -92.38% |
| Dec 31, 2018 | -34.44% |
| Sep 30, 2018 | -20.00% |
| Jun 30, 2018 | 24.80% |
| Mar 31, 2018 | -6.23% |
| Dec 31, 2017 | 111.18% |
| Sep 30, 2017 | 17.37% |
| Jun 30, 2017 | 18.15% |
| Mar 31, 2017 | 23.03% |
| Sep 30, 2016 | -174.44% |
| Jun 30, 2016 | -76.92% |
| Mar 31, 2016 | 8.45% |
| Dec 31, 2015 | 71.69% |
| Mar 31, 2015 | -80.43% |